SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES

(19)

(11)

EP 2 283 020 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	12.12.2012 Bulletin 2012/50

(45)	Mention of the grant of the patent:
	31.10.2012 Bulletin 2012/44

(21)	Application number: 09751280.0

(22)	Date of filing: 18.05.2009

(51)

International Patent Classification (IPC):

C07D 487/04^(2006.01)
A61P 35/00^(2006.01)

A61K 31/519^(2006.01)

(86)	International application number:
	PCT/US2009/044325

(87)	International publication number:
	WO 2009/143051 (26.11.2009 Gazette 2009/48)

(54)	SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES SUBSTITUIERTE IMIDAZOPYR- UND IMIDAZOTRIAZINE IMIDAZOPYRAZINES ET IMIDAZOTRIAZINES SUBSTITUÉES

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

(30)

Priority:

19.05.2008 US 54345 P

(43)	Date of publication of application:
	16.02.2011 Bulletin 2011/07

(73)	Proprietor: OSI Pharmaceuticals, LLC
	Farmingdale, NY 11735 (US)

(72)	Inventors:
	CREW, Andrew, P. Farmingdale, NY 11735 (US) JIN, Meizhong Farmingdale, NY 11735 (US) KADALBAJOO, Mridula Farmingdale, NY 11735 (US) KLEINBERG, Andrew Farmingdale, NY 11735 (US) MULVIHILL, Mark, J. Farmingdale, NY 11735 (US) WANG, Jing Farmingdale, NY 11735 (US)

(74)	Representative: Haile, Alison Victoria et al
	Mintz Levin, Cohn, Ferris, Glovsky and Popeo IP, LLP Alder Castle 10 Noble Street London EC2V 7JX London EC2V 7JX (GB)

(56)

References cited: :

WO-A-2006/004703
US-A1- 2006 046 977

WO-A-2007/075554

MULVIHILL ET AL: "Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors" BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 16, no. 3, 23 October 2007 (2007-10-23), pages 1359-1375, XP022453107 ISSN: 0968-0896
KOPECKY D J ET AL: "Identification and optimization of N<3>,N<6>-diaryl-1H-pyrazolo[3,4-d ]pyrimidine-3,6-diamines as a novel class of ACK1 inhibitors" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 18, no. 24, 15 December 2008 (2008-12-15), pages 6352-6356, XP025679027 ISSN: 0960-894X [retrieved on 2008-11-01]

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).